Letaplimab
- Generic Name
- Letaplimab
- Drug Type
- Biotech
- CAS Number
- 2283356-07-8
- Unique Ingredient Identifier
- BDN84I1TFE
- Background
Letaplimab is under investigation in clinical trial NCT04485052 (Efficacy and Safety Evaluation of IBI188 in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia).
IBI188 Combination Therapy in Solid Tumors
Phase 1
Terminated
- Conditions
- OsteosarcomaSolid TumorsLung Adenocarcinoma
- Interventions
- Drug: Cisplatin/Carboplatin
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT04861948
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04511975
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸New Jersey Center for Cancer Research, Brick, New Jersey, United States
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Phase 1
Suspended
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT04485052
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT03717103
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath